Chronic wireless communication between dual-chamber leadless pacemaker devices

Aveir DR (Abbott, Abbott Park, IL) is a dual-chamber leadless pacemaker (LP) system with distinct atrial and ventricular LPs (ALP, VLP) that communicate wirelessly to deliver atrioventricular synchronous pacing. Success rates of these implant-to-implant (i2i) transmissions have not been systematical...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Heart rhythm 2024-10
Hauptverfasser: Doshi, Rahul N., Ip, James E., Defaye, Pascal, Exner, Derek V., Reddy, Vivek Y., Hindricks, Gerhard, Canby, Robert, Shoda, Morio, Bongiorni, Maria G., Neužil, Petr, Callahan, Thomas, Badie, Nima, Ligon, David, Knops, Reinoud E.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Aveir DR (Abbott, Abbott Park, IL) is a dual-chamber leadless pacemaker (LP) system with distinct atrial and ventricular LPs (ALP, VLP) that communicate wirelessly to deliver atrioventricular synchronous pacing. Success rates of these implant-to-implant (i2i) transmissions have not been systematically evaluated. This study aims to evaluate chronic i2i success rates in a clinical setting. Patients meeting standard dual-chamber pacing indications were enrolled and implanted with dual-chamber LP systems as part of a prospective international clinical trial (Aveir DR i2i Study). The percent of successful i2i transmissions from ALP-to-VLP (A-to-V) and VLP-to-ALP (V-to-A) were interrogated from LPs in de novo patients using the device programmer at implant, discharge, and at 1, 3, and 6 months postimplant (1M, 3M, 6M). A total of 399 patients completed device implant and i2i diagnostic interrogation (62% male; age 69 years; 65% sinus node dysfunction, 32% atrioventricular [AV] block). Median A-to-V and V-to-A i2i success rates exceeded 90% of beats at all time-points from implant to 6M. The minority of patients with A-to-V or V-to-A i2i success in 90% of beats throughout the 6-month evaluation period. Communication success improved significantly over time postimplant for specific subgroups. Aveir DR i2i Study, ClinicalTrials.gov ID NCT05252702. [Display omitted]
ISSN:1547-5271
1556-3871
1556-3871
DOI:10.1016/j.hrthm.2024.10.020